Segment reporting (Tables)

6 Months Ended

Feb. 28, 2025

Segment Reporting [Abstract]

Reconciliation of Operating Income (Loss) from Segments to Consolidated

The following table reflects results of operations of the Company’s reportable segments (in millions):

	Three months ended				Six months ended
	February 28, 2025		February 29, 2024		February 28, 2025		February 29, 2024
Sales:
U.S. Retail Pharmacy
Pharmacy	$	23,432	$	21,508	$	48,143	$	43,892
Retail	6,948		7,353		13,103		13,913
Total	$	30,380	$	28,861	$	61,246	$	57,805
International
Pharmacy	$	837	$	898	$	1,749	$	1,824
Retail	2,182		2,158		4,298		4,090
Wholesale	3,041		2,966		6,438		5,940
Total	$	6,060	$	6,022	$	12,485	$	11,854
U.S. Healthcare	$	2,152	$	2,176	$	4,325	$	4,107
Corporate and Other 1	$	(4)	$	(6)	$	(8)	$	(6)
Walgreens Boots Alliance, Inc.	$	38,588	$	37,052	$	78,048	$	73,760
Adjusted operating income:
U.S. Retail Pharmacy	$	487	$	752	$	928	$	1,446
International	234		245		401		387
U.S. Healthcare	117		(34)		142		(129)
Corporate and Other	(52)		(63)		(93)		(117)
Walgreens Boots Alliance, Inc.	$	785	$	900	$	1,378	$	1,588

1.Includes certain eliminations.

The following table reconciles adjusted operating income to operating loss (in millions):

	Three months ended				Six months ended
	February 28, 2025		February 29, 2024		February 28, 2025		February 29, 2024
Adjusted operating income (Non-GAAP measure)	$	785	$	900	$	1,378	$	1,588
Impairment of goodwill, intangibles and long-lived assets	(5,343)		(13,090)		(5,343)		(13,090)
Acquisition-related amortization	(250)		(270)		(520)		(545)
Acquisition and disposition-related costs	(94)		(249)		(198)		(412)
Certain legal and regulatory accruals and settlements	(548)		(242)		(607)		(324)
Transformational cost management	(3)		(197)		12		(306)
Adjustments to equity earnings in Cencora	(33)		(22)		(109)		(72)
LIFO provision	(12)		—		(24)		(48)
Footprint optimization	(68)		—		(400)		—
Operating loss (GAAP)	$	(5,567)	$	(13,171)	$	(5,812)	$	(13,209)